Understanding the Risk Factors for Ozempic-Related Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Specific Exposure Awareness

If you or a loved one has developed gastroparesis after taking Ozempic, you may be wondering what factors increase the risk. The medical community has long studied how GLP-1 agonists affect gastrointestinal motility, and emerging research points to certain patient characteristics that may heighten susceptibility. This page reviews the current evidence on risk factors and what it means for your health.

Bridging to Ozempic and Gastroparesis

Building on the importance of timelines, we now turn to the specific case of Ozempic (semaglutide) and its association with gastroparesis. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action slows gastric emptying, a mechanism that can, in susceptible individuals, progress to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical diagnosis of gastroparesis typically involves gastric emptying scintigraphy showing delayed emptying after a standardized meal. The link between Ozempic and gastroparesis is supported by the drug's known gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal effects, which aligns with the mechanistic pathway of delayed gastric emptying.

Adequacy of Warnings and Risk Context

The adequacy of warnings regarding Ozempic and gastroparesis is a central risk anchor. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but it does not explicitly list gastroparesis as a warning or precaution. Instead, gastrointestinal adverse reactions are described as common, with nausea, vomiting, and diarrhea predominating. The label notes that these reactions often occur during dose escalation and may lead to discontinuation, but it does not specifically address the risk of developing chronic gastroparesis. This gap in explicit warning may be relevant for patients who experience persistent symptoms after treatment initiation or dose changes. For affected patients, settlement-related considerations hinge on whether the manufacturer adequately communicated the risk of severe gastrointestinal motility disorders. The timeline between exposure and documented harm is critical: symptoms typically emerge during dose escalation, but progression to gastroparesis may take weeks to months. Patients who develop gastroparesis after using Ozempic should document the start date of treatment, dose changes, and onset of symptoms such as persistent nausea, vomiting, or abdominal distension. Medical records confirming delayed gastric emptying via scintigraphy or other tests are essential for establishing harm.

California Statute of Limitations for Ozempic Claims

In California, the statute of limitations for product liability claims, including those related to Ozempic and gastroparesis, generally requires filing within two years from the date of injury or from when the injury was discovered or should have been discovered through reasonable diligence. For gastroparesis, which may develop gradually, the discovery date is often when a physician diagnoses the condition and links it to Ozempic use. Patients should consult with a legal professional to determine their specific filing deadline, as delays can bar recovery. Settlement-related considerations include the strength of evidence linking Ozempic to gastroparesis, the adequacy of warnings, and the severity of the patient's condition. Given the documented gastrointestinal adverse reactions in clinical trials and the absence of a specific gastroparesis warning, affected patients may have a viable claim if they can demonstrate that the manufacturer failed to warn about this risk. However, each case depends on individual facts, including the timeline of exposure, diagnosis, and any alternative causes of gastroparesis, such as diabetes itself, which is a common underlying condition in Ozempic users. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in California?

In California, the statute of limitations for product liability claims related to Ozempic and gastroparesis is generally two years from the date of injury or from when the injury was discovered or should have been discovered through reasonable diligence. For gastroparesis, the discovery date is often when a physician diagnoses the condition and links it to Ozempic use. It is crucial to consult with a legal professional to determine your specific filing deadline, as delays can bar recovery.

Does Ozempic's prescribing information warn about gastroparesis?

The prescribing information for Ozempic does not explicitly list gastroparesis as a warning or precaution. It includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but gastrointestinal adverse reactions are described as common, with nausea, vomiting, and diarrhea predominating. The label does not specifically address the risk of developing chronic gastroparesis, which may be relevant for patients who experience persistent symptoms.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.